Drug Name: NI-204
Company: Neurimmune Therapeutics
Location: Switzerland
Drug Type: Protein Biologic
Conditions: ALS, frontotemporal dementia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease
Mechanism Type: Misfolded SOD1 Clearance
Mechanism: NI-204 is a human-derived monoclonal conformational-specific antibody, which specifically targets misfolded superoxide dismutase (SOD1) that aims to prevent accumulation of SOD1 aggregates.
U.S. Status for ALS: Preclinical

[1] A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Maier, M et al. Sci Transl Med. 2018 Dec 5;10(470). pii: eaah3924.

Last updated March 11th, 2016

Share this: